Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (JapanExtension)

Inclusion Criteria

• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and any authorisations required by local law. Subjects who participated in and completed all protocol-related evaluations through Week 24 of Study 101MS203.
• Subjects of childbearing potential must practice effective contraception for 12 weeks after their last dose of study treatment.
• Must be willing to remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFNβ and long-term systemic corticosteroids) for the duration of the study.

Exclusion Criteria

• Any significant change in medical history since Study 101MS203, including laboratory tests, or current clinically important condition that in the opinion of the Investigator would have excluded the subject's participation in the previous study. The Investigator must re-review the subject's medical fitness for participation and consider diseases that would preclude treatment.
• Subjects from Study 101MS203 who discontinued study treatment due to an Adverse Event.
• Subjects who are determined to be persistently positive for anti-BG0002 antibodies based on prior testing.
• Treatment with any of the following medications between last dose of study treatment in Study 101MS203 and the start of this study: intravenous immunoglobulin (IVIg), plasmapheresis, cytapheresis, immunosuppressant medications (e.g., mitoxantrone, azathioprine, cyclophosphamide, methotrexate, cyclosporine, FTY720), immunomodulatory medications (including IFNβ and GA) total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination, any murine protein, any other therapeutic monocloncal antibody, or any 4-aminopyridine or related product.
• For female subjects, unless postmenopausal for at least 1 year or surgically sterile (does not include tubal ligation), unwillingness to practice effective contraception, as defined by the Investigator, during the study. Women considering becoming pregnant while on study are to be excluded.
• Female subjects who are currently pregnant or breast feeding, including subjects whose pregnancy test is positive at Week 0.
• Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.
• Subjects with any other condition, clinical finding, or reason that in the opinion of the Investigator and/or the Sponsor makes the subject unsuitable for enrolment into the study.